PRIMARY STUDY

Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB 1 R gene expression and reduces dyskinesias in a rat model of Parkinson's disease

Key Findings:  Data reveals significant differences in mRNA expression of CB1 receptor sites in a rat model of PD. Furthermore, the group of rats treated with arachidonyl-2'-chloroethylamide (ACEA), a full CB1 cannabinoid receptor agonist, experienced a significant reduction in abnormal involuntary movements.